Skip to main content

Olink Proteomics announces the availability of the most comprehensive, high-multiplex protein biomarker panel for mouse studies

Press Release   •   Dec 14, 2017 07:30 EST

Uppsala, Sweden, December 14, 2017 – Olink Proteomics today announced the launch of Olink® MOUSE EXPLORATORY, offering 92 high-quality assays to measure mouse proteins. The panel is based on the same, well-established Proximity Extension Assay (PEA) technology behind Olink’s portfolio of high-multiplex panels for human protein biomarker discovery, and has been developed to the same high standards of validation and quality control.

Mouse studies provide important biological information that can play a key role in understanding and treating human diseases. The knowledge accumulated from mouse studies has made a significant contribution to our understanding of human biology, and mouse models are becoming increasingly important in translational medicine studies and the drug development process1. Powerful tools that can reliably measure multiple proteins in mouse samples remain scarce, however, and Olink Proteomics has developed this new panel in response to clear and frequent requests from customers.

The Mouse Exploratory panel enables simultaneous analysis of 92 protein biomarkers, consuming just 1 µL of biological sample such as serum or plasma. This is an important consideration when working with small animals where sample volumes are very limited. The proteins assayed in the panel encompass a broad range of biological functions and pathways, making this an ideal tool for exploratory studies aimed at discovering new biomarkers and protein signatures in mouse studies. Moreover, the human equivalents of these proteins are all known to be detectable in serum and plasma, increasing the likelihood that any findings made in mice can be readily investigated in human studies. More details about this panel and the protein biomarkers assays included can be found on the Olink MOUSE EXPLORATORY product page.

“We are delighted to be able to offer this new panel to the many scientists who have expressed a strong desire to be able to use our innovative technology in their mouse studies. Olink’s mission is to support the implementation of precision medicine by providing the optimal tools for protein biomarker discovery and development along the entire chain, from early exploratory studies to future clinical application. With this panel for mouse studies, we have taken an additional important step that supports academic research and the pharmaceutical industry to better understand biology and speed up the development of effective drugs.

Based on a library of almost 1000 proteins, our human panels are very well-established in human clinical research, with more than 400 000 samples analyzed world-wide and over 100 peer-reviewed publications now in the literature. While we will continue to focus on the expansion of our human protein library and develop many more human panels, the launch of this panel for mouse studies illustrates our commitment to provide precision proteomics tools that support a broad range of customer needs and applications.”

says Andrea Ballagi, VP Sales & Marketing at Olink Proteomics.

Product and technology information
Each Olink panel offers high-throughput multiplex immunoassays that measure 92 proteins simultaneously using only one microliter of serum, plasma, tumor cell lysate, or almost any other type of biological sample. Thousands of samples per week can be analyzed using these panels, which greatly accelerates the speed of protein biomarker discovery.

Olink’s assays are based on the proprietary Proximity Extension Assay (PEA) technology developed by Olink. PEA is a homogeneous assay that uses pairs of antibodies equipped with DNA reporter molecules which upon target binding give rise to new DNA amplicons, each ID-barcoding their respective antigens. Cross-reactive events are not detected since the sequence design allows only the correctly matched antibody pairs to give rise to a signal. The amplicons are subsequently quantified by high throughput real-time PCR. This dual recognition, DNA-coupled method provides exceptional readout specificity and enables the panels to achieve a combination of high multiplexing level and data quality that cannot be matched using standard immunoassay techniques. An animation overviewing how the technology works and what it is used for can be viewed on Olink’s YouTube channel.

For research use only. Not for use in diagnostic procedures.

Contact information
Andrea Ballagi, MD, PhD, MBA
VP Sales & Marketing
Phone: +46-18-444 3970
E-mail: info@olink.com

1Zuberi & Lutz 2016

About Olink Proteomics 

Through our dedication to innovation, quality, rigor and transparency, Swedish company Olink Proteomics’ groundbreaking solutions help scientists make research decisions more quickly and confidently through robust, multiplex biomarker analysis. Our immunoassay panels enable rapid, high-throughput analysis with exceptional data quality and minimal consumption of precious biological samples. Only 1 µL of sample is needed to address 92 biomarkers simultaneously and each panel is sufficient for 96 samples, generating more than 9 000 data points from each run. Each panel is focused on a specific area of disease or biology, targeting 92 validated and/or exploratory biomarkers that have been carefully selected in collaboration with leading experts in the field. All assays are rigorously quality controlled and our validation data is made freely available. Customers can obtain the panels as ready-to-use kits to run the assays themselves, or can choose to let our in-house experts run their samples for them, using our Analysis Service in Uppsala or Boston.

Olink Proteomics is headquartered in Uppsala, Sweden, with a regional office and service laboratory for the U.S. organization in Watertown, MA.

For more information, please visit www.olink.com.

Olink® is a registered trademark of Olink Proteomics AB.

Attached Files

PDF document

Comments (0)

Add comment

Comment

Agree With Privacy Policy